Chemomab Therapeutics Ltd.
CMMBDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
CMMB Earnings Report
EPS Est: $0.00 | FQ end 2026-06
How CMMB's past catalysts played out
Anti-human CCL24 monoclonal antibody (CM-101)
Primary Sclerosing Cholangitis
5 mg/kg CM-101
Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Anti-human CCL24 monoclonal antibody (CM-101) | Phase 2 | Primary Sclerosing Cholangitis | - | - |
5 mg/kg CM-101 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Chemomab Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Chemomab Therapeutics Ltd.'s (CMMB) pipeline across Phase 2. Its lead program is Anti-human CCL24 monoclonal antibody (CM-101) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Chemomab Therapeutics Ltd.'s next FDA catalyst?→
Chemomab Therapeutics Ltd.'s (CMMB) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMMB biotech catalysts?→
Add CMMB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Chemomab Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.